NasdaqGM - Delayed Quote USD

Bionomics Limited (BNOX)

0.9219 -0.0281 (-2.96%)
At close: May 13 at 4:00 PM EDT
0.9200 -0.01 (-0.81%)
Pre-Market: 8:11 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 508.54k -- 1973
Mr. Adrian Hinton BEC, F.C.A. Financial Controller 197.71k -- 1953
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer -- -- 1963
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Consultant Chief Medical Officer of Clinical Neuroscience 67.32k -- --
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations -- -- --
Ms. Suzanne Irwin B.Com., FCIS Company Secretary -- -- --

Bionomics Limited

200 Greenhill Road
Eastwood, SA 5063
Australia
61 8 8150 7400 https://www.bionomics.com.au
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Corporate Governance

Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Feb 14, 2024
    SC 13G/A: Tender Offer/Acquisition Reports
    See Full Filing
  • Jan 17, 2024
    20-F/A: Periodic Financial Reports
    See Full Filing
  • Jan 11, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Jan 04, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Nov 30, 2023
    6-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

May 14, 2024 - May 22, 2024
Bionomics Limited Earnings Call

Related Tickers

OKYO OKYO Pharma Limited
1.4800
+1.37%
 
KPRX Kiora Pharmaceuticals, Inc.
0.5097
+3.60%
 
RNXT RenovoRx, Inc.
1.4100
-1.40%
 
CING Cingulate Inc.
0.7909
+3.24%
 
INM InMed Pharmaceuticals Inc.
0.2798
+6.31%
 
ORGS Orgenesis Inc.
0.6090
+5.00%
 
PMVP PMV Pharmaceuticals, Inc.
2.1300
+4.41%
 
BRTX BioRestorative Therapies, Inc.
1.3100
-4.38%
 
DRMA Dermata Therapeutics, Inc.
0.3800
+11.44%
 
CYTO Altamira Therapeutics Ltd.
1.4400
0.00%